New York State Teachers Retirement System Boosts Stock Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

New York State Teachers Retirement System grew its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 3,284.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 99,812 shares of the company’s stock after acquiring an additional 96,863 shares during the period. New York State Teachers Retirement System’s holdings in Hims & Hers Health were worth $2,413,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in HIMS. Louisiana State Employees Retirement System bought a new position in Hims & Hers Health in the fourth quarter valued at $2,234,000. Kestra Private Wealth Services LLC grew its stake in shares of Hims & Hers Health by 105.1% during the fourth quarter. Kestra Private Wealth Services LLC now owns 29,106 shares of the company’s stock valued at $704,000 after buying an additional 14,912 shares during the last quarter. State of Alaska Department of Revenue purchased a new stake in shares of Hims & Hers Health during the fourth quarter worth about $2,628,000. Kercheville Advisors LLC purchased a new stake in shares of Hims & Hers Health during the fourth quarter worth about $470,000. Finally, Crewe Advisors LLC purchased a new stake in shares of Hims & Hers Health during the fourth quarter worth about $28,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Trading Down 26.1 %

Shares of HIMS stock opened at $49.10 on Friday. The stock has a market capitalization of $10.73 billion, a price-to-earnings ratio of 111.58 and a beta of 1.35. Hims & Hers Health, Inc. has a 12-month low of $9.25 and a 12-month high of $72.98. The stock’s 50-day moving average price is $35.05 and its 200-day moving average price is $25.76.

Analysts Set New Price Targets

Several analysts have commented on the stock. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. Piper Sandler lifted their target price on shares of Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a report on Monday, January 6th. Bank of America boosted their price target on Hims & Hers Health from $18.00 to $21.00 and gave the stock an “underperform” rating in a research note on Thursday. Citigroup downgraded shares of Hims & Hers Health from a “neutral” rating to a “sell” rating and lifted their target price for the stock from $24.00 to $25.00 in a research report on Friday, January 10th. Finally, TD Cowen reaffirmed a “buy” rating and set a $28.00 target price on shares of Hims & Hers Health in a report on Wednesday, November 20th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $28.53.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 128,127 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $58.27, for a total value of $7,465,960.29. Following the transaction, the chief executive officer now owns 97,687 shares of the company’s stock, valued at $5,692,221.49. This represents a 56.74 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Soleil Boughton sold 4,152 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total transaction of $251,984.88. Following the completion of the transaction, the insider now directly owns 157,345 shares in the company, valued at $9,549,268.05. This represents a 2.57 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,184,611 shares of company stock valued at $40,338,442. 17.71% of the stock is owned by corporate insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.